MSC-derived vesicles and AAT for viral infection treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective means for treating and preventing viral infections, particularly for severe acute respiratory syndrome (SARS-CoV-2), with no established treatments capable of balancing immune responses to prevent excessive inflammation and tissue damage while allowing effective immune responses against pathogens.
Innovation Solution
A pharmaceutical composition combining extra-cellular vesicles isolated from mesenchymal stem cells (MSCs) and Alpha-1 antitrypsin (AAT) protein, which are administered topically or locally to the respiratory tract or oral cavity, to modulate immune responses and inhibit viral infection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used for viral infections, then treatment options are limited, but immune responses may cause excessive inflammation and tissue damage
Solution Approach 1:
The patent combines two distinct therapeutic agents: Alpha-1 antitrypsin (AAT) protein and mesenchymal stem cell-derived extra-cellular vesicles (MSC-EVs). AAT provides protease inhibition to prevent viral entry and reduce inflammation, while MSC-EVs deliver immunomodulatory factors and miRNAs to regulate immune responses. This combination therapy addresses both viral infection control and immune response modulation simultaneously, resolving the contradiction between effective treatment and harmful inflammation.
Solution Approach 2:
The invention creates a composite pharmaceutical composition integrating AAT protein with MSC-derived extra-cellular vesicles. This composite formulation synergistically combines the protease-inhibiting properties of AAT with the immunomodulatory capabilities of MSC-EVs, achieving both viral entry prevention and balanced immune response regulation, thereby treating viral infections without causing excessive inflammation.
2Reliability
If immunomodulatory factors are increased to enhance immune response, then viral infection prevention improves, but immune system balance may be disrupted
Solution Approach 1:
MSC-derived extra-cellular vesicles act as intermediaries that carry immunomodulatory factors, including anti-inflammatory miRNAs (such as miR-146a, miR-155) and cytokines, to regulate immune cell activity. These vesicles modulate the immune response in a controlled manner, enhancing antiviral immunity while preventing excessive inflammation through the balanced delivery of regulatory molecules, thus maintaining immune system balance.
Solution Approach 2:
The patent utilizes changes in the immunomodulatory profile of MSC-EVs under different culture conditions (such as IFN-γ stimulation) to optimize their therapeutic effect. The vesicles can be engineered to contain specific ratios of pro-inflammatory and anti-inflammatory factors, allowing precise control over immune response intensity and duration, thereby enhancing viral defense while maintaining immune balance.
3Productivity
If protease activity is increased to facilitate viral entry, then viral infection efficiency improves, but tissue damage increases
Solution Approach 1:
The patent exploits the dual nature of proteases by using AAT to selectively inhibit harmful protease activity while allowing necessary viral entry mechanisms to proceed. AAT specifically inhibits neutrophil elastase and other proteases that cause tissue damage, while not completely blocking all protease-dependent viral entry processes. This converts the potentially harmful protease activity into a controlled process that enables viral entry without excessive tissue destruction.
Solution Approach 2:
The invention applies local quality control by having AAT concentrate at sites of viral infection and inflammation, where it specifically inhibits proteases causing tissue damage. The MSC-EVs also deliver factors locally to modulate immune cell activity at the infection site. This localized action allows viral entry to proceed where needed while preventing protease-mediated tissue damage in surrounding healthy tissues.
Data Source
AI summary
A method for treating and/or reducing the risk of a viral infection in a human subject, including administering a pharmaceutical composition including Alpha-1 antitrypsin (AAT) protein to a subject in need thereof, wherein the composition is administered by inhalation.